Onco-Hu® Mouse Models

June 27, 2022

This video explores Onco-Hu® models, a robust immuno-oncology platform for efficacy testing of novel immunotherapies targeting T cells and myeloid cells. The platform is based on NSG™ and NSG™-SGM3 transgenic mice, dually engrafted with human CD34+ hematopoietic stem cells (HSCs) and clinically relevant PDX Live™ low passage tumors.

Onco-Hu® Mouse Models

How-to Guide for Selecting Xenografts & Mouse Models for Preclinical Cancer Research

What Do Experimental Mice Really Cost?

Comparing Immune-Humanized Mouse Platforms for Preclinical Applications

Using Cre-lox Technology in Mouse Modeling

Designing Reproducible Preclinical Research Studies

Comparing Immunodeficient Models for Cancer, Immunity, and Transplant Research

The Consequences of Sex Bias in Preclinical Research

Translatable Efficacy & Safety Testing of mAb, Bispecific, & CAR T Therapies

Key Considerations to Optimize Preclinical Aging Studies

De-Risk Therapeutic Antibody Drug Development Using Humanized FcRn Platforms (Oct. 24, 2023)

New Immune-humanized Models Support More Diverse Human Immune Cell Lineages

Rapid In Vivo Evaluation of Immuno-Modulatory Therapies Using Hu-PBMC NSG™ Mice

Comparing Mouse Models for Obesity and Diabetes Research

The Many Faces of C57BL/6 Mice: Research Impact of B6 Substrain Differences

Essential Tips for Choosing and Using Mouse Models in Research

In Vivo Platforms for Autoimmune Pharmacology: MS-EAE Capabilities

Support the 3 R’s with Effective Mouse Colony Management Practices

Preclinical Assessment of Investigational Gene Therapy Products for Neuroscience

In Vivo Drug Discovery Platforms for Amyotrophic Lateral Sclerosis

Mouse Models of Coronavirus Infection